According to Bernstein, valuations across the Indian biopharma sector have re-rated significantly, with the Nifty Pharma index trading slightly above its 10-year average multiple of 30.5 times its one-year forward earnings. However, it noted that its preferred stocks continue to trade below their long-term average valuations.
